- ICH GCP
- EU: n kliinisten tutkimusten rekisteri
Viimeisimmät kokeilut
EudraCT Number: 2004-000530-37 | Sponsor Protocol Number: 24978 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Serono International S.A. | |||||||||||||
Full Title: A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjec... | |||||||||||||
Medical condition: Psoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickene... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001662-41 | Sponsor Protocol Number: BAP00154 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Basilea Pharmaceutica Ltd | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind Study of Ceftobiprole versus Vancomycin in the Treatment of Complicated Skin and Skin Structure Infections | |||||||||||||
Medical condition: Complicated skin and skin structure infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001730-17 | Sponsor Protocol Number: BAP00248/307 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: A Phase 3, Randomized Double-Blind Study of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia | |||||||||||||
Medical condition: Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) HU (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001069-17 | Sponsor Protocol Number: CSPI135ZDE04 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Novartis Pharma GmbH | |||||||||||||
Full Title: A double-blind, active-controlled, randomized, multicenter, parallel-group 2 day comparison of 1000 mg propyphenazone / 80 mg codeine (applied as two suppositories) combination therapy versus a 100... | |||||||||||||
Medical condition: acute, at least moderate to severe biliary or urogenital pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001648-64 | Sponsor Protocol Number: No EP-24332T-A014 | Start Date: 2004-09-16 | ||||||
Sponsor Name: ardana LTD | ||||||||
Full Title: A Phase II multicentre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix 90 mg, long-acting f... | ||||||||
Medical condition: advanced prostate cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||
Trial protocol: LT (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001217-15 | Sponsor Protocol Number: 85/04/04 | Start Date: 2004-09-16 | ||||||
Sponsor Name: Lassila Riitta | ||||||||
Full Title: PRO-FEIBA. Asetelma on selkeä etenevä satunnaistettu kaksisuuntainen tutkimus aktivoitujen hyytymistekijöiden (aPCC, activated prothrombin complex concentrate) vaikutuksesta vaikeaa A hemofiliaa sa... | ||||||||
Medical condition: A-hemofilia | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |||||||
Trial protocol: FI (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001590-26 | Sponsor Protocol Number: MAS QUE NADA | Start Date: 2004-09-15 | |||||||||||
Sponsor Name: OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: NATIONAL, MULTICENTER, RANDOMIZED,OPEN STUDY TO EVALUATE EFFICACY AND SAFETY OF LAMIVUDINE (300 MG QD) MONOTHERAPY AS AN ALTERNATIVE TO THERAPEUTIC INTERRUPTION IN PAZIENTS AFFECTED BY HIV-1, IN VI... | |||||||||||||
Medical condition: HIV MONOTHERAPY TREATMENT , AS THERAPEUTIC MAINTENANCE, DURING INTERRUPTION OF ANTIVIRAL THERAPY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000050-23 | Sponsor Protocol Number: 28130 | Start Date: 2004-09-15 | |||||||||||
Sponsor Name: NV Organon | |||||||||||||
Full Title: Prospective, double-blind, randomized, placebo-controlled dose finding study of the efficacy and safety of 2 target doses of Org 34517 used as adjunctive therapy in subjects with psychotic major de... | |||||||||||||
Medical condition: Psychotic major depression (major depressive episode, severe, with psychotic features) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001827-39 | Sponsor Protocol Number: SIFIM | Start Date: 2004-09-15 | |||||||||||
Sponsor Name: OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: NATIONAL, MULTICENTER, RANDOMISED, OPEN STUDY TO VALUATE THE EFFICACY OF DIFFERENT THERAPEUTIC STRATEGIES TO AVOID THE IMMUNOLOGIC FAILURE IN MULTIRESISTENT HIV-1 INFECTED PATIENTS. | |||||||||||||
Medical condition: HIV TREATMENT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000638-35 | Sponsor Protocol Number: CZOL446N2312 | Start Date: 2004-09-15 | ||||||
Sponsor Name: Novartis Sverige AB | ||||||||
Full Title: A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12... | ||||||||
Medical condition: Postmenopausal Osteoporosis | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: SE (Completed) ES (Completed) | ||||||||
Trial results: View results |